Related Experiment Videos
Endothelin-1: possible implications in pulmonary vascular disease
1Department of Physiology and Biophysics, Georgetown University Medical Center, Washington, DC 20007, USA.
Heart & Lung : the Journal of Critical Care
|July 1, 1997
Summary
Endothelin-1 (ET-1) has varied effects on pulmonary vessels, influenced by vessel tone, ET-1 dose, and maturation. Elevated ET-1 levels in pulmonary hypertension suggest ET-1 antagonists could be a valuable treatment.
Area of Science:
- Cardiovascular Physiology
- Pulmonary Medicine
- Endocrinology
Background:
- Endothelin-1 (ET-1) is a potent vasoconstrictor peptide.
- Pulmonary hypertension is characterized by elevated pulmonary arterial pressure.
- The role of ET-1 in pulmonary vascular regulation is complex and multifactorial.
Purpose of the Study:
- To investigate the vasoactive properties of endothelin-1 (ET-1) in an animal model.
- To elucidate the mechanisms mediating ET-1's action in the pulmonary vasculature.
- To assess the clinical relevance of ET-1 in pulmonary hypertension.
Main Methods:
- Animal modeling of pulmonary hypertension.
- Vascular reactivity studies assessing ET-1's effects.
- Measurement of plasma ET-1 levels.
Main Results:
- ET-1's vasoactive effects varied with pulmonary vessel tone, ET-1 dose, and vessel maturation.
- Endothelium-derived nitric oxide, prostaglandins, and electrolytes mediate ET-1's action.
- Elevated plasma ET-1 levels were observed in animal models and human subjects with pulmonary hypertension.
Conclusions:
- ET-1 plays a significant role in the pathophysiology of pulmonary hypertension.
- Targeting ET-1 with antagonists presents a potential therapeutic strategy.
- ET-1 antagonists may offer a novel treatment for pediatric and adult pulmonary hypertension.